ArticleRisk management and healthcare policy2024

Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens.

Lan-Fang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.